產品
BioNTech colorectal cancer vaccine trial fails; shares fall 8%
BioNTech's colorectal cancer vaccine trial failed, and the article reports BioNTech shares fell 8% on the news. The setback lands days after the positive late-stage readout from the rival Moderna/Merck cancer-vaccine program.
大盤 開啟原文 ↗